Immulone

Immulone - Atospharma.com

Non Specific Immune Enhancer

Properties and actions:

Caffeic acid derivatives (mainly chicoric acid), alkamides and polysaccharides are the main effective groups in Echinacea, the main active constituent of Immulone.
Immulone contains also vitamin c which supports the integrity of mucous membranes. Immulone stimulates the immune response by enhancing phagocytosis by macrophages and activation of natural killer cells. Immulone increases cytokine production, such as interferon which helps in controlling viral infection. Immulone has mild direct antibacterial activity and direct anti-inflammatory activity.
Immulone has anti-hyaluronidase enzyme activity which prevents spreading of infection and accelerates recovery. Immulone increases phagocytosis of candida by 45% and decreases the rate of recurrence of fungal infections. Through these actions, Immulone enhances the resistance to viral, bacterial and fungal infections in healthy subjects and shortens the duration of illness and helps in rapid recovery. 

Indications:

  • Prevention and treatment of common cold and influenza
  • Prophylactic therapy in cases of increased susceptibility to infections
  • Inflammatory skin diseases. Recurrent vaginal candidiasis

Dosage:

Age
Dosage
Timing
Children
(5 - 9years) 
1-2 lozenges
1 time/day
Adolescents
(10 - 14years)
1 lozenge
3 times/day
Adults & Adolescents
(> 14 years)
2 lozenges
3 times/day

Contraindications:

  • Hypersensitivity to the active substance
  • In accordance with general principles, not to be used in patients with progressive systemic diseases such as tuberculosis, collagenoses, multiple sclerosis, HIV infection and autoimmune diseases

Side Effects:

  • In rare cases hypersensitivity reactions, e.g. skin reactions, can occur

Each lozenge contains:

  • Echinacea purpurea extract 150 mg
  • Vitamin C 50 mg 

Pack size:

  • 20 lozenges in 2 blisters

Precautions / Drug interactions:

  • The duration of continuous treatment should not exceed 8 weeks
  • No reported drug interactions.